Clinical Handbook of Psychotropic Drugs -

Clinical Handbook of Psychotropic Drugs

Buch | Spiralbindung
480 Seiten
2023 | 25. Auflage
Hogrefe Publishing (Verlag)
978-0-88937-632-8 (ISBN)
84,95 inkl. MwSt
The classic reference to psychotropic medications for psychiatrists, psychologists, physicians, pharmacists, and nurses, packed with the latest drugs, completely revised sections, and much more.
The Clinical Handbook of Psychotropic Drugs has become a standard reference and working tool for psychiatrists, psychologists, physicians, pharmacists, nurses, and other mental health professionals.

  • Independent, unbiased, up-to-date
  • Packed with unique, easy-to-read comparison charts and tables (dosages, side effects, pharmacokinetics, interactions...) for a quick overview of treatment options
  • Succinct, bulleted information on all classes of medication: on- and off-label indications, side effects, interactions, pharmacodynamics, precautions in the young, the elderly, and pregnancy, nursing implications, and much more - all you need to know for each class of drug
  • Potential interactions and side effects summarized in comparison charts
  • With instantly recognizable icons and in full color throughout, allowing you to find at a glance all the information you seek
  • Clearly written patient information sheets available for download as printable PDF files

This book is a must for everyone who needs an up-to-date, easy-to-use, comprehensive summary of all the most relevant information about psychotropic drugs.

New in this edition:
  • Antidepressants chapter includes a new section on the NMDA receptor antagonist/CYP2D6 inhibitor combination product (dextromethorphan/bupropion; Auvelity extended-release tablets)
  • Antipsychotics updates include revised Clozapine monitoring tables which now also contain monitoring requirements for patients with or without non-benign ethnic neutropenia
  • Mood Stabilisers sections on Lithium and Anticonvulsants extensively revised
  • Dementia chapter includes a new section on Lecanemab (Leqembi), a fast-track FDA approved treatment for Alzheimer's disease
  • Treatment of Substance Use Disorders includes revisions to Buprenorphine dosing section to include a rapid micro-induction method (Bernese method) that allows treatment to start without waiting for patient to be in withdrawal
  • Unapproved treatments of Psychiatric Disorders, Natural Health Products, and Pharmacogenetic chapters all substantially revised
  • New formulations and trade names include: Invega Hafyera (paliperidone long-acting 6-monthly IM injection), Subutex (buprenorphine sublingual tablets), Quviviq (daridorexant tablets)

Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada; British Columbia Mental Health & Addictions Research Institute, Vancouver, BC, Canada.

Kalyna Z. Bezchlibnyk-Butler, BScPharm, FCSHP, Toronto, ON, Canada.

David D. Kim, BSc, MSc, PhD, Department of Anesthesiology, Pharmacology and Therapeutics, University of British Columbia, Vancouver, BC, Canada.

Erscheinungsdatum
Verlagsort Toronto
Sprache englisch
Maße 279 x 216 mm
Themenwelt Geisteswissenschaften Psychologie
Medizin / Pharmazie Medizinische Fachgebiete Pharmakologie / Pharmakotherapie
Medizin / Pharmazie Medizinische Fachgebiete Psychiatrie / Psychotherapie
Pflege Fachpflege Neurologie / Psychiatrie
Medizin / Pharmazie Pharmazie Apothekenpraxis
Medizin / Pharmazie Pharmazie PTA / PKA
ISBN-10 0-88937-632-8 / 0889376328
ISBN-13 978-0-88937-632-8 / 9780889376328
Zustand Neuware
Haben Sie eine Frage zum Produkt?
Mehr entdecken
aus dem Bereich